May 29, 2020

The Post Wired

News On Trending

Earnings Alert: BioSpecifics Technologies Corp. (NASDAQ: BSTC)

Spread the love

BioSpecifics Technologies Corp. (NASDAQ: BSTC) reported change of 4.91% to $63.43 with the recent traded volume of 69938 shares in most recent trading session compared to an average volume of 47.00K. The stock was down over last five days period with -7.10%. The one month performance of stock was -14.63%. BSTC shares are at 2.60% for the quarter and driving a 36.36% return over the course of the past year and is now at -0.23% since this point in 2018.

BioSpecifics Technologies Corp. (NASDAQ: BSTC) declared its financial results for the fourth quarter and full year ended December 31, 2018 and provided a corporate update.

Fourth Quarter and Full Year 2018 Financial Results

BioSpecifics reported net income of $6.2 million for the fourth quarter ended December 31, 2018, or $0.85 per basic share and $0.84 per share on a fully diluted basis, compared to net income of $2.6 million, or $0.37 per basic share and $0.36 per share on a fully diluted basis, for the same period in 2017. For the full year ended December 31, 2018, the Company reported a net income of $20.1 million, or $2.77 per basic share and $2.73 per share on a fully diluted basis, compared to a net income of $11.3 million, or $1.58 per basic share and $1.55 per share on a fully diluted basis for the same period in 2017.

Total revenue for the fourth quarter ended December 31, 2018 was $9.9 million, compared to $6.7 million for the same period in 2017. For the full year ended December 31, 2018, total revenue was $33.0 million, compared to $27.4 million for the same period in 2017. The increase in total revenues for the quarterly and year-end periods was primarily due to increased sales of XIAFLEX® for the treatment of Peyronie’s Disease and Dupuytren’s Contracture reported to us by Endo.

Royalty and mark-up on cost of goods sold (COGS) revenues recognized under BioSpecifics’ agreement with Endo for the fourth quarter ended December 31, 2018 were $9.9 million compared to $6.7 million for the same period in 2017, an increase of $3.2 million or 48 percent. Total royalty and mark-up on COGS revenues for the year ended December 31, 2018 increased to $32.9 million as compared to $27.4 million in the same period in 2017. This increase in royalties and the mark-up on COGS in each quarterly and year end periods was primarily due to increased sales of XIAFLEX® for the treatment of Peyronie’s Disease and Dupuytren’s Contracture reported to us by Endo.

Licensing revenue consists of licensing fees, sublicensing fees and milestones. No licensing revenue was recognized for the fourth quarter ended December 31, 2018 as compared to approximately $4,000 for the same period in 2017. Licensing fees recognized for the years ended December 31, 2018 and 2017 were $40,000 and $18,000, respectively. Development licensing fees recognized for CCH are related to the cash payments received under the License Agreement in prior years and amortized over the expected development period. For the year ended December 31, 2018, we recognized the remaining nonrefundable upfront product license in accordance with ASC 606.

Research and development (R&D) expenses for the fourth quarter ended December 31, 2018 were $0.2 million compared to $0.3 million for the same period in 2017. For the year ended December 31, 2018, R&D expenses were $0.8 million, compared to $1.2 million in the same period in 2017.

General and administrative expenses for the fourth quarter ended December 31, 2018 were $2.5 million, compared to $1.6 million for the same period in 2017. For the year ended December 31, 2018, general administrative expenses were $8.8 million, compared to $8.5 million in the same period in 2017.

Provision for income taxes for the fourth quarter ended December 31, 2018 were $1.5 million, compared to $2.4 million for the same period in 2017. For the year ended December 31, 2018, provision for income taxes were $4.7 million as compared to $7.0 million in the same period of 2017.

As of December 31, 2018, BioSpecifics had cash and cash equivalents and investments of $82.0 million, compared to $65.1 million as of December 31, 2017.

As of December 31, 2018, BioSpecifics had 7.3 million shares of common stock outstanding.

The Company has earnings of $ 17.60M and made $6.60 sales for the last 12 months. Its quarter to quarter sales remained 26.20% and sales observed at 19.70% over past 5 years. The stock beta value is 1.29. BSTC is 9.46% upward its 200-day moving average. On a similar note, the stock is -5.39% above its 50-day moving average. The average volatility for the week and month was at 3.97% 4.09% respectively. The company holds 7.38M shares outstanding and 5.33M shares are floated in market.

Single Column Posts

2 min read

Spain's La Liga will continue on 11 June with next season beginning on 12 September, says the alliance's leader Javier Tebas. On Monday, Tebas said...

3 min read

The 125th gathering between Borussia Dortmund and Bayern Munich will without a doubt be the most foreseen match of this crowdless Bundesliga period. No less...

3 min read

Borussia Dortmund host Bayern Munich this evening in one of the biggest matches of the Bundesliga season. Bayern currently enjoy a four point lead at...

3 min read

Borussia Dortmund vs. Bayern Munich Match Info Der Klassiker is set for Tuesday at Signal Iduna Park as runner up Borussia Dortmund invites in front...

5 min read

We will give us one of the most exceptionally foreseen matches, in the Bundesliga as well as in Europe, as Borussia Dortmund lock horns with...

3 min read

How to watch Tiger vs Phil live on Kodi, Android, iOS, Fire TV Stick and other devices from US, UK, Canada and rest of the...

6 min read

On the off chance that you love golf, at that point missing the 2020 Tiger Woods versus Phil Mickelson is simply impossible. There is such...

3 min read

Tiger Woods vs Phil Mickelson II : Start time, TV channel with Tom Brady and Peyton Manning Aspect Old rivals Tiger Woods and Phil Mickelson...

3 min read

There isn't obviously superior to a Sunday evening of watching golf and sleeping, however for fans who have been denied of live games for a...

4 min read

Champions for Charity 2020 Live:: The decades-long contentions between Tom Brady and Peyton Manning proceed with the assistance of another, the one between Tiger Woods...